Journal of Diabetes Research

Journal of Diabetes Research / 2018 / Article

Review Article | Open Access

Volume 2018 |Article ID 1890978 |

You Lv, Xue Zhao, Weiying Guo, Ying Gao, Shuo Yang, Zhuo Li, Guixia Wang, "The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus", Journal of Diabetes Research, vol. 2018, Article ID 1890978, 7 pages, 2018.

The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus

Academic Editor: Peter Bolli
Received26 Oct 2017
Revised16 Feb 2018
Accepted18 Mar 2018
Published07 May 2018


Metabolic diseases, especially diabetes mellitus, have become global health issues. The etiology of diabetes mellitus can be attributed to genetic and/or environmental factors. Current evidence suggests the association of gut microbiota with metabolic diseases. However, the effects of glucose-lowering agents on gut microbiota are poorly understood. Several studies revealed that these agents affect the composition and diversity of gut microbiota and consequently improve glucose metabolism and energy balance. Possible underlying mechanisms include affecting gene expression, lowering levels of inflammatory cytokines, and regulating the production of short-chain fatty acids. In addition, gut microbiota may alleviate adverse effects caused by glucose-lowering agents, and this can be especially beneficial in diabetic patients who experience severe gastrointestinal side effects and have to discontinue these agents. In conclusion, gut microbiota may provide a novel viewpoint for the treatment of patients with diabetes mellitus.

1. Introduction

Over the past few decades, metabolic diseases such as type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, and cardiovascular diseases have become major public health issues all over the world. Accordingly, an increasing amount of research has been conducted to further investigate the pathogenesis, phenotypes, and treatments of such diseases. One of the most common metabolic disorders is T2DM, which is characterized by chronic hyperglycemia that can be attributed to genetic and/or environmental factors. Recently, the role played by gut microbiota in T2DM has gained increasing attention, with several studies investigating the composition and function of gut microbiota in T2DM [1].

It was found that, for a standard-weight male, the ratio of bacterial cells to human cells is approximately 1 : 3, with an uncertainty of 25% and a variation of 53% [2]. Several studies reported an association between gut microbiota and metabolic diseases [39], with some studies presenting the differences between gut microbiota in T2DM patients and healthy individuals [3, 10]. For example, Qin et al. [11] reported that many opportunistic pathogens, such as Bacteroides caccae, Clostridium hathewayi, Clostridium ramosum, Clostridium symbiosum, Eggerthella lenta, and Escherichia coli, are enriched in T2DM patients. In addition, Karlsson et al. [12] reported an increase in Lactobacillus spp. (Lactobacillus gasseri JV-V03, Lactobacillus gasseri SJ-9E-US, Lactobacillus gasseri 202-4, and Lactobacillus salivarius ACS-116-V-Col5a) and a decrease in Clostridium spp. (Clostridium beijerinckii NCIMB 8052, Clostridium sp. 7_2_43FAA, Clostridium botulinum B str. Eklund 17B, Clostridium botulinum E3 str. Alaska E43, and Clostridium thermocellum DSM 1313) in T2DM patients. Treatment with metformin affects gut microbiota, and thus, it might be an important confounder in the above studies. Gut microbiota were found to control body weight after bariatric surgery, regulate plasma glucose and insulin levels, maintain the intestinal epithelial barrier integrity, and lower the levels of inflammatory cytokines [1316]. Moreover, some probiotic supplements exhibit beneficial metabolic properties [1517]. All this information suggests that gut microbiota may be involved in the etiology of diabetes mellitus.

Short-chain fatty acids (SCFAs) including acetate (C2), propionate (C3), butyrate (C4), and valerate (C5) are produced by anaerobic bacteria through the fermentation of nondigestible dietary polysaccharides in the colon [1820]. Some researchers suggested that a common form of gut microbiota alteration in T2DM is the reduction in butyrate-producing bacteria [11, 21]. Sodium butyrate was found to lower plasma glucose and lipid levels, improve insulin resistance, and reduce gluconeogenesis in diabetic rats [22]. Thus, SCFAs might have a promising role in the prevention and treatment of diabetes mellitus.

Currently available therapeutic options for T2DM, especially glucose-lowering agents, target different pathophysiologic processes. A large body of evidence suggests that gut microbiota and SCFAs exhibit positive effects on glucose-lowering agents in T2DM. Glucose-lowering agents can influence the composition of gut microbiota [23, 24] and affect the production of SCFAs, thereby leading to significant beneficial effects [1, 25, 26]. Moreover, adverse effects of glucose-lowering agents may be improved by altered gut microbiota [27, 28]. This review summarizes current information on the relationship between frequently used glucose-lowering agents and gut microbiota (Table 1) to better understand the role of the intestinal microenvironment in the treatment of diabetes mellitus.

Glucose-lowering agentGut microbiota alterationResearch subjects
Increased abundanceDecreased abundance

BiguanidesMetforminEscherichia [1, 12, 24]
Shigella [12]
Klebsiella [12]
Salmonella [12]
Adlercreutzia [30]
Clostridium cocleatum [43]
Akkermansia muciniphila [24, 43, 44]
Bifidobacterium adolescentis [24]
Intestinibacter [1, 24]
Clostridium [12]
Eubacterium [12]
T2DM patients [1, 24, 30]
Old women with T2DM [12]
HFD-fed mice [43, 44]

α-Glucosidase inhibitorsAcarboseBifidobacterium longum [23, 55]
Lactobacillus gasseri [23]
Lactobacillus [58]
Dialister [58]
Bacteroides plebeius [23]
Bacteroides dorei/vulgatus [23]
Clostridium bolteae [23]
Butyricicoccus [58]
Phascolarctobacterium [58]
Ruminococcus [58]
T2DM patients [23, 55]
Prediabetic patients [58]

PPAR-γ partial agonist (Chinese medicine)Danshensu Bingpian ZhiAkkermansia muciniphila [67]Helicobacter marmotae [67]HFD-fed mice [67]

DPP-4 inhibitorVildagliptinBacteroidetes [68]Prevotellaceae [68]
Ruminococcaceae [68]
HFD/STZ SD rats [68]
SitagliptinRoseburia [13]
Bifdobacterium [13]
Blautia [13]HF/HC-STZ SD rats [13]

T2DM: type 2 diabetes mellitus; HFD: high-fat diet; PPAR-γ: peroxisome proliferator-activated receptor γ; DPP-4: dipeptidyl peptidase-4; STZ: streptozotocin; HF/HC: high fat/high carbohydrate; SD rats: Sprague Dawley rats.

2. Metformin and Gut Microbiota

2.1. Metformin Mechanism of Action and Side Effects

Metformin is a biguanide that reduces hepatic glucose production, increases glucose uptake by peripheral tissues, and activates AMP-dependent protein kinase (AMPK). Metformin is actively transported into cells by organic cation transporters (OCT) [29, 30]. The mechanism of action of metformin is not yet fully understood. In an experimental study on mice with alanine knock-in mutations in both acetyl-CoA carboxylase (Acc) 1 (Ser79) and Acc2 (Ser212), treatment with metformin reduced hepatic lipogenesis and lipid accumulation via activating AMPK and inhibited both Acc1 and Acc2, thereby increasing insulin sensitivity [31]. Duca et al. [32] found that metformin could activate duodenal mucosal AMPK and attenuate hepatic glucose production in a rat model of high-fat diet (HFD). In addition, Miller et al. [33] found that metformin lowers the fasting glucose level by inhibiting glucagon-stimulated cyclic adenosine monophosphate production, which leads to reduced protein kinase A activity and glucagon-stimulated glucose output. Metformin was also found to alter intestinal microbiota [34].

Currently, metformin is the first-line treatment for T2DM and is recommended by the American Diabetes Association and the European Association for the Study of Diabetes with proven efficacy, safety, and low cost [35]. It can lower plasma glucose and insulin levels, improve lipid profiles, and promote modest weight loss. An extended-release formulation of metformin that has fewer gastrointestinal (GI) side effects, for example, diarrhea, anorexia, nausea, and metallic taste, is also available [21, 29]. About 30% of the patients treated with metformin report suffering from GI adverse effects [1]. In a previous clinical study in which 360 T2DM patients were administered a new prescription of metformin for 3 months, about 88% of the participants reported single or multiple GI symptoms, including diarrhea, heartburn, and nausea [36]. Possible underlying mechanisms for metformin adverse effects include stimulation of intestinal serotonin secretion, changes in incretin and glucose metabolism, bile salt malabsorption, and high intestinal metformin concentrations after oral administration [37]. Since OCT1 is involved in the absorption of metformin from the intestinal lumen, its inhibition results in increased metformin intolerance [37]. Recent data illustrated that delayed-release metformin performs its action predominantly in the intestine, so it is considered to be safe for T2DM patients with renal impairment [38].

2.2. The Effect of Metformin on Gut Microbiota in T2DM

Metformin has pleiotropic effects. It accumulates mainly in the intestine, where its concentration is nearly 300 times higher than its plasma concentration [39]. Thus, the intestine is the major site of metformin exposure and is responsible for its glucose-lowering effect [38]. In 1984, Bonora et al. [40] found that intravenous administration of metformin did not improve glucose metabolism compared to oral administration, which suggests the importance of the intestine in the regulation of glucose metabolism by metformin. Metformin was found to increase the life span of Caenorhabditis elegans cocultured with Escherichia coli by altering microbial folate and methionine metabolism [41], which suggests that the effects of metformin on aging in nematodes are microbiota dependent. Recently, the relationship between metformin and the gut has been comprehensively reviewed [21]; researchers indicated that metformin can affect the gut microenvironment by modulating glucose uptake and utilization, increasing glucagon-like peptide-1 (GLP-1) and bile acid levels and altering gut microbiota. In conclusion, the interaction between metformin and gut microbiota may contribute to the pleiotropic effects of metformin.

A large body of evidence confirms the effects of metformin on intestinal microbiota. The abundance of Akkermansia muciniphila was found to be decreased in obesity and diabetes [9], while higher baseline levels were associated with improvements in the cardiometabolic parameters of obesity [11, 42]. Experimental studies revealed that the abundances of Akkermansia muciniphila [43, 44] and Clostridium cocleatum [43] increased significantly in HFD-fed mice after metformin treatment. The higher abundance of Akkermansia muciniphila was involved in maintaining mucin layer integrity [45, 46], and the changes in gut microbiota were attributed to SCFA-producing bacteria in human and animal guts [45, 46]. It is suggested that the effects of metformin on the abundance of these species may indirectly contribute to its modulatory effects on glucose metabolism and other metabolic processes. These results suggest that the therapeutic effect of metformin might be partially mediated by the intestinal tract.

Forslund et al. [1] found that metformin-treated T2DM patients exhibited decreased abundances of Intestinibacter spp. and increased abundances of Escherichia spp. However, the latter was only found in Danish and Swedish populations. In a cross-sectional study that recruited 145 European old women with T2DM, impaired glucose tolerance, or normal glucose tolerance, patients treated with metformin showed different gut microbial composition than those who were not treated with metformin [12]. Napolitano et al. also evaluated T2DM with and without metformin monotherapy to characterize the gut-based mechanisms of metformin, and their results showed that Adlercreutzia spp. were significantly elevated in fecal samples of metformin-treated patients [30]. Wu et al. [24] found that the altered microbiota mainly belonged to the phyla γ-Proteobacteria and Firmicutes. They found an increase in Escherichia spp. and a decrease in Intestinibacter spp., as well as a significant increase in fecal propionate and butyrate concentrations in the metformin group. A possible underlying mechanism for metformin-microbiota interaction is regulating the expression of genes encoding for metalloproteins in gut bacteria. These results demonstrate the influence of metformin on gut microbial diversity and the role of the intestine in the glucose-lowering effect of metformin.

Unfortunately, alteration of gut microbiota by metformin may contribute to its GI intolerance [21]. Greenway et al. [27] reported a case in which a 30-year-old man newly diagnosed with T2DM was treated with a cobiotic supplement containing inulin, beta-glucan, and blueberry pomace extract for 8 weeks. This patient exhibited balanced glycemic control and alleviated GI side effects of metformin. In addition, Burton et al. [28] found that the combination of metformin with GI microbiome modulator (GIMM) in T2DM patients who experienced GI intolerance to metformin resulted in better glucose tolerance compared to placebo and significantly improved fasting glucose levels. These results demonstrate that a safe dietary supplement may improve the efficacy and tolerability of metformin, possibly through the alteration of gut microbiota. Thus, gut microbiota may serve as a novel approach to alleviate metformin adverse effects and consequently improve patient compliance.

3. The Effect of Acarbose on Gut Microbiota in T2DM

Accumulating evidence suggests that postprandial blood glucose level is a powerful predictor of diabetic cardiovascular events [47, 48]. As a classical α-glucosidase inhibitor, acarbose lowers postprandial blood glucose levels by delaying glucose absorption, as it inhibits the enzyme that cleaves oligosaccharides into mono- and disaccharides in the intestinal lumen [29]. The control of postprandial hyperglycemia is especially important in Asia due to the traditional carbohydrate-rich dietary pattern [49]. In a randomized, open-label, noninferiority clinical trial recruiting Chinese patients newly diagnosed with T2DM, treatment with acarbose as initial therapy showed similar glucose-lowering efficacy to that of metformin [50]. Therefore, acarbose is an effective and safe antidiabetic agent, especially for the control of postprandial hyperglycemia. The major cause of acarbose side effects (e.g., diarrhea, flatulence, and abdominal distention) is the increased delivery of oligosaccharides to the large intestine. However, these side effects can be ameliorated by gradual upward dose titration [29]. Previous studies indicated that acarbose treatment could reduce the risk of cardiovascular events in diabetic patients [5154]. The detailed underlying mechanisms for this cardiovascular protective function are only partially understood [55], but they can be attributed to the ability of acarbose to neutralize oxidative stress by increasing H2 production in the GI tract (GIT) [56]. However, the results of Chang et al. did not support a cardiovascular protective effect of acarbose compared to metformin in Taiwan populations [57].

A series of recent clinical trials clarified the relationship between acarbose and gut microbiota. For example, in a clinical study, 95 Chinese T2DM patients were distributed into 2 groups; one group was treated with acarbose while the other was not. At baseline, diabetic patients showed lower levels of Bifidobacterium longum and higher levels of Enterococcus faecalis than healthy volunteers [55]. After 4 weeks of treatment, acarbose-treated patients showed increased Bifidobacterium longum and decreased lipopolysaccharide and prothrombin activator inhibitor-1 levels [55]. These results suggest that acarbose treatment could alter gut microbiota and reduce the levels of inflammatory cytokines in diabetic patients. Another randomized, double-blind, controlled crossover trial recruiting prediabetic Chinese individuals demonstrated that acarbose treatment significantly altered the diversity and composition of gut microbiota [58]. In addition, Gu et al. [23] revealed that acarbose could regulate the gut microbiota of T2DM patients, thereby modulating bile acid metabolism and contributing to beneficial effects on host metabolism.

Although α-glucosidase inhibitors have been widely used clinically, there is an ongoing interest in probiotics or gut microbiota as biotherapeutic agents for some metabolic diseases. Panwar et al. [59] found that Lactobacillus strains exhibit glucosidase-inhibitory effects and regulate blood glucose responses to carbohydrates in vivo. As mentioned previously, SCFAs play an important role in diabetes mellitus. Acarbose was found to increase serum butyrate levels in individuals with impaired glucose tolerance. The underlying mechanism for this effect might be that acarbose increases the fermentation of insoluble fibers in the colon [25]. Similarly, a clinical study showed that butyrate production is significantly increased during acarbose treatment, whereas the production of acetate and propionate is significantly decreased [26].

The beneficial effects of acarbose on diabetes mellitus, such as reduction of inflammatory cytokines and regulation of SCFA levels, can be related to the alteration of intestinal microbiota. However, whether there is an association between the cardiovascular protective action of acarbose and gut microbiota is not yet clear.

4. Glucagon-Like Peptide-1 (GLP-1) and Gut Microbiota

Endocrine peptides play an important role in the crosstalk between gut microbiota and host metabolism. Everard and Cani [60] reviewed the effects of certain dietary fibers on the gut microbiota and host homeostasis and on the secretion of enteroendocrine peptides. As discussed earlier in this review, gut microbiota ferments nondigestible polysaccharides in the colon producing SCFAs and thus influences host glucose and energy homeostasis. It has been elucidated that SCFAs activate GPR41 and GPR43 and thus regulate the secretion of enteroendocrine peptides [6163]. Known as a gut hormone, GLP-1 is involved in glucose metabolism, appetite regulation, and gastric emptying. The mechanism by which gut microbiota could accelerate the GI motility was mainly attributed to the suppression of GLP-1 receptor expression in the GIT [64]. Recently, several studies have proven the significant glucose-lowering effect of GLP-1-based therapies; GLP-1 receptor agonists like exenatide and liraglutide could promote insulin secretion, suppress glucagon levels, slow gastric emptying, accelerate satiety, induce weight loss, and lower the risk of hypoglycemia [29]. Grasset et al. [65] demonstrated that GLP-1 sensitivity was modulated by gut microbiota through nitric oxide-dependent mechanism in the enteric nervous system. Their results indicated that new hypoglycemic agents based on GLP-1 should focus on the research of patients’ intestinal microbiota.

Currently, the association between gut microbiota and intestinal peptides involved in energy and glucose homeostasis has been well reported. However, the relationship between GLP-1 receptor agonists and gut microbiota is not yet clear; further clinical trials are needed to understand this relationship.

5. Other Glucose-Lowering Agents and Gut Microbiota

Pioglitazone is a thiazolidinedione that can reduce insulin resistance by binding to peroxisome proliferator-activated receptor γ (PPAR-γ) nuclear receptor [29]. Previous experimental studies identified the difference in gut microbial structure between KKAy mice and C57BL/6J mice by showing a higher abundance of Bacteroides spp. in the intestine of KKAy mice [66]. Pioglitazone was shown to improve gut microbial structure of KKAy mice, but it decreased microbial diversity [66]. The traditional Chinese medicine Danshensu Bingpian Zhi (DBZ), a PPAR-γ partial agonist, not only improved the phenotypes of metabolic syndrome but also increased the Bacteroidetes/Firmicutes ratio, resulting in an increase in Akkermansia muciniphila and a decrease in Helicobacter marmotae in HFD-fed mice [67]. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was also found to improve gut microbial structure. The underlying mechanism is not clear; however, it can be mediated by relieving intestinal wall edema, alleviating intestinal inflammation, and maintaining the intestinal mucosal barrier integrity [13]. Vildagliptin, another DPP-4 inhibitor, was found to significantly reduce microbiota diversity in diabetic rats and to normalize the Bacteroidetes/Firmicutes ratio [68]. Sodium/glucose cotransporter (SGLT) is a novel therapeutic target in T2DM. LX4211, a dual inhibitor of SGLT1 and SGLT2, could reduce glucose absorption by inhibiting SGLT1 and stimulate the release of GLP-1 and peptide YY. These effects may be mediated by SCFAs produced by cecal fermentation of unabsorbed glucose [69]. Although no definite evidence indicates that SGLT inhibitor has direct effects on gut microbiota to improve glycemic control, it should be noted that SGLT inhibition exerts positive effects on metabolic diseases [70].

Other glucose-lowering agents such as cathelicidin antimicrobial peptide [71], phlorizin [72], and transglucosidase [73] were also proven to have beneficial modulatory effects on gut microbiota composition, glucose homeostasis, insulin resistance, and β cell function.

Taken together, these studies are of great significance for understanding the role of gut microbiota as novel therapeutic targets in diabetes mellitus. However, further studies are still needed to confirm the hypothesis.

6. Conclusion

In conclusion, the alteration of gut microbiota is a pivotal process in the pathogenesis and progression of metabolic diseases. The association between glucose-lowering agents and gut microbiota is not yet fully understood. Understanding the effects of glucose-lowering agents on gut microbiota is of great importance to further understand the etiopathogenesis, diagnosis, treatment, adverse effects, and prognosis of metabolic diseases.

Conflicts of Interest

The authors declare that there are no conflicts of interest.


The research was supported by the Fund for Science and Technology Development Plan of Jilin Province (20170623092TC-04) to You Lv.


  1. K. Forslund, F. Hildebrand, T. Nielsen et al., “Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota,” Nature, vol. 528, no. 7581, pp. 262–266, 2015. View at: Publisher Site | Google Scholar
  2. R. Sender, S. Fuchs, and R. Milo, “Revised estimates for the number of human and bacteria cells in the body,” PLoS Biology, vol. 14, no. 8, article e1002533, 2016. View at: Publisher Site | Google Scholar
  3. K.-A. Lê, Y. Li, X. Xu et al., “Alterations in fecal Lactobacillus and Bifidobacterium species in type 2 diabetic patients in Southern China population,” Frontiers in Physiology, vol. 3, p. 496, 2013. View at: Publisher Site | Google Scholar
  4. A. J. Cox, N. P. West, and A. W. Cripps, “Obesity, inflammation, and the gut microbiota,” The Lancet Diabetes & Endocrinology, vol. 3, no. 3, pp. 207–215, 2015. View at: Publisher Site | Google Scholar
  5. A. V. Hartstra, K. E. C. Bouter, F. Bäckhed, and M. Nieuwdorp, “Insights into the role of the microbiome in obesity and type 2 diabetes,” Diabetes Care, vol. 38, no. 1, pp. 159–165, 2015. View at: Publisher Site | Google Scholar
  6. G. Blandino, R. Inturri, F. Lazzara, M. Di Rosa, and L. Malaguarnera, “Impact of gut microbiota on diabetes mellitus,” Diabetes & Metabolism, vol. 42, no. 5, pp. 303–315, 2016. View at: Publisher Site | Google Scholar
  7. C. L. Boulange, A. L. Neves, J. Chilloux, J. K. Nicholson, and M. E. Dumas, “Impact of the gut microbiota on inflammation, obesity, and metabolic disease,” Genome Medicine, vol. 8, no. 1, p. 42, 2016. View at: Publisher Site | Google Scholar
  8. R. J. Perry, L. Peng, N. A. Barry et al., “Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome,” Nature, vol. 534, no. 7606, pp. 213–217, 2016. View at: Publisher Site | Google Scholar
  9. H. Plovier, A. Everard, C. Druart et al., “A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice,” Nature Medicine, vol. 23, no. 1, pp. 107–113, 2017. View at: Publisher Site | Google Scholar
  10. J. Sato, A. Kanazawa, F. Ikeda et al., “Gut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes,” Diabetes Care, vol. 37, no. 8, pp. 2343–2350, 2014. View at: Publisher Site | Google Scholar
  11. J. Qin, Y. Li, Z. Cai et al., “A metagenome-wide association study of gut microbiota in type 2 diabetes,” Nature, vol. 490, no. 7418, pp. 55–60, 2012. View at: Publisher Site | Google Scholar
  12. F. H. Karlsson, V. Tremaroli, I. Nookaew et al., “Gut metagenome in European women with normal, impaired and diabetic glucose control,” Nature, vol. 498, no. 7452, pp. 99–103, 2013. View at: Publisher Site | Google Scholar
  13. X. Yan, B. Feng, P. Li, Z. Tang, and L. Wang, “Microflora disturbance during progression of glucose intolerance and effect of sitagliptin: an animal study,” Journal of Diabetes Research, vol. 2016, Article ID 2093171, 10 pages, 2016. View at: Publisher Site | Google Scholar
  14. A. P. Liou, M. Paziuk, J. M. Luevano, S. Machineni, P. J. Turnbaugh Jr., and L. M. Kaplan, “Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity,” Science Translational Medicine, vol. 5, no. 178, article 178ra141, 2013. View at: Publisher Site | Google Scholar
  15. P. D. Cani, A. M. Neyrinck, F. Fava et al., “Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia,” Diabetologia, vol. 50, no. 11, pp. 2374–2383, 2007. View at: Publisher Site | Google Scholar
  16. P. Tian, B. Li, C. He et al., “Antidiabetic (type 2) effects of Lactobacillus G15 and Q14 in rats through regulation of intestinal permeability and microbiota,” Food & Function, vol. 7, no. 9, pp. 3789–3797, 2016. View at: Publisher Site | Google Scholar
  17. K. L. Wickens, C. A. Barthow, R. Murphy et al., “Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial,” British Journal of Nutrition, vol. 117, no. 6, pp. 804–813, 2017. View at: Publisher Site | Google Scholar
  18. A. Salonen, L. Lahti, J. Salojarvi et al., “Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men,” The ISME Journal, vol. 8, no. 11, pp. 2218–2230, 2014. View at: Publisher Site | Google Scholar
  19. G. den Besten, K. van Eunen, A. K. Groen, K. Venema, D. J. Reijngoud, and B. M. Bakker, “The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism,” Journal of Lipid Research, vol. 54, no. 9, pp. 2325–2340, 2013. View at: Publisher Site | Google Scholar
  20. J. Tan, C. McKenzie, M. Potamitis, A. N. Thorburn, C. R. Mackay, and L. Macia, “Chapter Three - the role of short-chain fatty acids in health and disease,” Advances in Immunology, vol. 121, pp. 91–119, 2014. View at: Publisher Site | Google Scholar
  21. L. J. McCreight, C. J. Bailey, and E. R. Pearson, “Metformin and the gastrointestinal tract,” Diabetologia, vol. 59, no. 3, pp. 426–435, 2016. View at: Publisher Site | Google Scholar
  22. S. Khan and G. Jena, “Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: a comparative study with metformin,” Chemico-Biological Interactions, vol. 254, pp. 124–134, 2016. View at: Publisher Site | Google Scholar
  23. Y. Gu, X. Wang, J. Li et al., “Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment,” Nature Communications, vol. 8, no. 1, p. 1785, 2017. View at: Publisher Site | Google Scholar
  24. H. Wu, E. Esteve, V. Tremaroli et al., “Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug,” Nature Medicine, vol. 23, no. 7, pp. 850–858, 2017. View at: Publisher Site | Google Scholar
  25. T. M. Wolever and J. L. Chiasson, “Acarbose raises serum butyrate in human subjects with impaired glucose tolerance,” British Journal of Nutrition, vol. 84, no. 1, pp. 57–61, 2000. View at: Google Scholar
  26. G. A. Weaver, C. T. Tangel, J. A. Krause et al., “Acarbose enhances human colonic butyrate production,” The Journal of Nutrition, vol. 127, no. 5, pp. 717–723, 1997. View at: Publisher Site | Google Scholar
  27. F. Greenway, S. Wang, and M. Heiman, “A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report,” Beneficial Microbes, vol. 5, no. 1, pp. 29–32, 2014. View at: Publisher Site | Google Scholar
  28. J. H. Burton, M. Johnson, J. Johnson, D. S. Hsia, F. L. Greenway, and M. L. Heiman, “Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels,” Journal of Diabetes Science and Technology, vol. 9, no. 4, pp. 808–814, 2015. View at: Publisher Site | Google Scholar
  29. D. L. Longo, Harrison’s Principles of Internal Medicine, McGraw-Hill, New York, 18th edition, 2012.
  30. A. Napolitano, S. Miller, A. W. Nicholls et al., “Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus,” PLoS One, vol. 9, no. 7, article e100778, 2014. View at: Publisher Site | Google Scholar
  31. M. D. Fullerton, S. Galic, K. Marcinko et al., “Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin,” Nature Medicine, vol. 19, no. 12, pp. 1649–1654, 2013. View at: Publisher Site | Google Scholar
  32. F. A. Duca, C. D. Côté, B. A. Rasmussen et al., “Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats,” Nature Medicine, vol. 21, no. 5, pp. 506–511, 2015. View at: Publisher Site | Google Scholar
  33. R. A. Miller, Q. Chu, J. Xie, M. Foretz, B. Viollet, and M. J. Birnbaum, “Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP,” Nature, vol. 494, no. 7436, pp. 256–260, 2013. View at: Publisher Site | Google Scholar
  34. K. Y. Hur and M. S. Lee, “New mechanisms of metformin action: focusing on mitochondria and the gut,” Journal of Diabetes Investigation, vol. 6, no. 6, pp. 600–609, 2015. View at: Publisher Site | Google Scholar
  35. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetes Care, vol. 35, no. 6, pp. 1364–1379, 2012. View at: Publisher Site | Google Scholar
  36. H. Florez, J. Luo, S. Castillo-Florez et al., “Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes,” Postgraduate Medicine, vol. 122, no. 2, pp. 112–120, 2010. View at: Publisher Site | Google Scholar
  37. T. Dujic, K. Zhou, L. A. Donnelly, R. Tavendale, C. N. A. Palmer, and E. R. Pearson, “Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study,” Diabetes, vol. 64, no. 5, pp. 1786–1793, 2015. View at: Publisher Site | Google Scholar
  38. J. B. Buse, R. A. DeFronzo, J. Rosenstock et al., “The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies,” Diabetes Care, vol. 39, no. 2, pp. 198–205, 2016. View at: Publisher Site | Google Scholar
  39. C. J. Bailey, C. Wilcock, and J. H. B. Scarpello, “Metformin and the intestine,” Diabetologia, vol. 51, no. 8, pp. 1552-1553, 2008. View at: Publisher Site | Google Scholar
  40. E. Bonora, M. Cigolini, O. Bosello et al., “Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects,” Current Medical Research and Opinion, vol. 9, no. 1, pp. 47–51, 1984. View at: Publisher Site | Google Scholar
  41. F. Cabreiro, C. Au, K. Y. Leung et al., “Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism,” Cell, vol. 153, no. 1, pp. 228–239, 2013. View at: Publisher Site | Google Scholar
  42. E. Le Chatelier, T. Nielsen, J. Qin et al., “Richness of human gut microbiome correlates with metabolic markers,” Nature, vol. 500, no. 7464, pp. 541–546, 2013. View at: Publisher Site | Google Scholar
  43. H. Lee and G. Ko, “Effect of metformin on metabolic improvement and gut microbiota,” Applied and Environmental Microbiology, vol. 80, no. 19, pp. 5935–5943, 2014. View at: Publisher Site | Google Scholar
  44. N. R. Shin, J. C. Lee, H. Y. Lee et al., “An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice,” Gut, vol. 63, no. 5, pp. 727–735, 2014. View at: Publisher Site | Google Scholar
  45. J. de la Cuesta-Zuluaga, N. T. Mueller, V. Corrales-Agudelo et al., “Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid–producing microbiota in the gut,” Diabetes Care, vol. 40, no. 1, pp. 54–62, 2017. View at: Publisher Site | Google Scholar
  46. X. Zhang, Y. Zhao, J. Xu et al., “Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats,” Scientific Reports, vol. 5, no. 1, article 14405, 2015. View at: Publisher Site | Google Scholar
  47. The DECODE study group, European Diabetes Epidemiology Group, and Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe, “Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria,” The Lancet, vol. 354, no. 9179, pp. 617–621, 1999. View at: Publisher Site | Google Scholar
  48. T. Nakagami and the DECODA Study Group, “Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin,” Diabetologia, vol. 47, no. 3, pp. 385–394, 2004. View at: Publisher Site | Google Scholar
  49. S. R. Joshi, E. Standl, N. Tong, P. Shah, S. Kalra, and R. Rathod, “Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review,” Expert Opinion on Pharmacotherapy, vol. 16, no. 13, pp. 1959–1981, 2015. View at: Publisher Site | Google Scholar
  50. W. Yang, J. Liu, Z. Shan et al., “Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial,” The Lancet Diabetes & Endocrinology, vol. 2, no. 1, pp. 46–55, 2014. View at: Publisher Site | Google Scholar
  51. J. L. Chiasson, R. G. Josse, R. Gomis et al., “Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial,” JAMA, vol. 290, no. 4, pp. 486–494, 2003. View at: Publisher Site | Google Scholar
  52. M. Hanefeld, M. Cagatay, T. Petrowitsch, D. Neuser, D. Petzinna, and M. Rupp, “Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies,” European Heart Journal, vol. 25, no. 1, pp. 10–16, 2004. View at: Publisher Site | Google Scholar
  53. J. M. Chen, C. W. Chang, Y. C. Lin, J. T. Horng, and W. H. H. Sheu, “Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study,” Journal of Diabetes Research, vol. 2014, Article ID 812628, 6 pages, 2014. View at: Publisher Site | Google Scholar
  54. E. Standl, M. J. Theodorakis, M. Erbach, O. Schnell, and J. Tuomilehto, “On the potential of acarbose to reduce cardiovascular disease,” Cardiovascular Diabetology, vol. 13, no. 1, p. 81, 2014. View at: Publisher Site | Google Scholar
  55. B. Su, H. Liu, J. Li et al., “Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus,” Journal of Diabetes, vol. 7, no. 5, pp. 729–739, 2015. View at: Publisher Site | Google Scholar
  56. Y. Suzuki, M. Sano, K. Hayashida, I. Ohsawa, S. Ohta, and K. Fukuda, “Are the effects of α-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract?” FEBS Letters, vol. 583, no. 13, pp. 2157–2159, 2009. View at: Publisher Site | Google Scholar
  57. C. H. Chang, Y. C. Chang, J. W. Lin, S. T. Chen, L. M. Chuang, and M. S. Lai, “Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 3, pp. 1121–1129, 2015. View at: Publisher Site | Google Scholar
  58. X. Zhang, Z. Fang, C. Zhang et al., “Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial,” Diabetes Therapy, vol. 8, no. 2, pp. 293–307, 2017. View at: Publisher Site | Google Scholar
  59. H. Panwar, D. Calderwood, I. R. Grant, S. Grover, and B. D. Green, “Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential,” European Journal of Nutrition, vol. 53, no. 7, pp. 1465–1474, 2014. View at: Publisher Site | Google Scholar
  60. A. Everard and P. D. Cani, “Gut microbiota and GLP-1,” Reviews in Endocrine and Metabolic Disorders, vol. 15, no. 3, pp. 189–196, 2014. View at: Publisher Site | Google Scholar
  61. B. S. Samuel, A. Shaito, T. Motoike et al., “Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 43, pp. 16767–16772, 2008. View at: Publisher Site | Google Scholar
  62. M. K. Nøhr, M. H. Pedersen, A. Gille et al., “GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes,” Endocrinology, vol. 154, no. 10, pp. 3552–3564, 2013. View at: Publisher Site | Google Scholar
  63. G. Tolhurst, H. Heffron, Y. S. Lam et al., “Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2,” Diabetes, vol. 61, no. 2, pp. 364–371, 2012. View at: Publisher Site | Google Scholar
  64. M. Yang, H. Fukui, H. Eda et al., “Involvement of gut microbiota in association between GLP-1/GLP-1 receptor expression and gastrointestinal motility,” American Journal of Physiology. Gastrointestinal and Liver Physiology, vol. 312, no. 4, pp. G367–G373, 2017. View at: Publisher Site | Google Scholar
  65. E. Grasset, A. Puel, J. Charpentier et al., “A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism,” Cell Metabolism, vol. 26, no. 1, p. 278, 2017. View at: Publisher Site | Google Scholar
  66. Y. Li, L. Han, M. Xu, J. Guo, M. Feng, and X. Wang, “The primary research on the gut microbes in KKAy mice,” Indian Journal of Microbiology, vol. 54, no. 1, pp. 12–19, 2014. View at: Publisher Site | Google Scholar
  67. P. Xu, F. Hong, J. Wang et al., “DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis,” Biochimica et Biophysica Acta (BBA) – General Subjects, vol. 1861, no. 11, Part A, pp. 2690–2701, 2017. View at: Publisher Site | Google Scholar
  68. Q. Zhang, X. Xiao, M. Li et al., “Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats,” PLoS One, vol. 12, no. 10, article e0184735, 2017. View at: Publisher Site | Google Scholar
  69. D. R. Powell, M. Smith, J. Greer et al., “LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)–mediated absorption of intestinal glucose,” The Journal of Pharmacology and Experimental Therapeutics, vol. 345, no. 2, pp. 250–259, 2013. View at: Publisher Site | Google Scholar
  70. A. Lehmann and P. J. Hornby, “Intestinal SGLT1 in metabolic health and disease,” American Journal of Physiology Gastrointestinal and Liver Physiology, vol. 310, no. 11, pp. G887–G898, 2016. View at: Publisher Site | Google Scholar
  71. L. D. Pound, C. Patrick, C. E. Eberhard et al., “Cathelicidin antimicrobial peptide: a novel regulator of islet function, islet regeneration, and selected gut bacteria,” Diabetes, vol. 64, no. 12, pp. 4135–4147, 2015. View at: Publisher Site | Google Scholar
  72. X. Mei, X. Zhang, Z. Wang et al., “Insulin sensitivity-enhancing activity of phlorizin is associated with lipopolysaccharide decrease and gut microbiota changes in obese and type 2 diabetes (db/db) mice,” Journal of Agricultural and Food Chemistry, vol. 64, no. 40, pp. 7502–7511, 2016. View at: Publisher Site | Google Scholar
  73. M. Sasaki, N. Ogasawara, Y. Funaki et al., “Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study,” BMC Gastroenterology, vol. 13, no. 1, p. 81, 2013. View at: Publisher Site | Google Scholar

Copyright © 2018 You Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.